Cytotoxic CD8+ T cells in cancer and cancer immunotherapy

Research output: Contribution to journal › Review › Research › peer-review

Standard

Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. / Raskov, Hans; Orhan, Adile; Christensen, Jan Pravsgaard; Gögenur, Ismail.

In: British Journal of Cancer, Vol. 124, 2021, p. 359–367.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Raskov, H, Orhan, A, Christensen, JP & Gögenur, I 2021, 'Cytotoxic CD8+ T cells in cancer and cancer immunotherapy', British Journal of Cancer, vol. 124, pp. 359–367. https://doi.org/10.1038/s41416-020-01048-4

APA

Raskov, H., Orhan, A., Christensen, J. P., & Gögenur, I. (2021). Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. British Journal of Cancer, 124, 359–367. https://doi.org/10.1038/s41416-020-01048-4

Vancouver

Raskov H, Orhan A, Christensen JP, Gögenur I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. British Journal of Cancer. 2021;124:359–367. https://doi.org/10.1038/s41416-020-01048-4

Author

Raskov, Hans ; Orhan, Adile ; Christensen, Jan Pravsgaard ; Gögenur, Ismail. / Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. In: British Journal of Cancer. 2021 ; Vol. 124. pp. 359–367.

Bibtex

@article{990e1fcea68e404893d4ae84aa719dca,
title = "Cytotoxic CD8+ T cells in cancer and cancer immunotherapy",
abstract = "The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most powerful effectors in the anticancer immune response and form the backbone of current successful cancer immunotherapies. Immune-checkpoint inhibitors are designed to target immune-inhibitory receptors that function to regulate the immune response, whereas adoptive cell-transfer therapies use CD8+ T cells with genetically modified receptors—chimaeric antigen receptors—to specify and enhance CD8+ T-cell functionality. New generations of cytotoxic T cells with genetically modified or synthetic receptors are being developed and evaluated in clinical trials. Furthermore, combinatory regimens might optimise treatment effects and reduce adverse events. This review summarises advances in research on the most prominent immune effectors in cancer and cancer immunotherapy, cytotoxic T cells, and discusses possible implications for future cancer treatment.",
author = "Hans Raskov and Adile Orhan and Christensen, {Jan Pravsgaard} and Ismail G{\"o}genur",
year = "2021",
doi = "10.1038/s41416-020-01048-4",
language = "English",
volume = "124",
pages = "359–367",
journal = "The British journal of cancer. Supplement",
issn = "0007-0920",
publisher = "nature publishing group",

}

RIS

TY - JOUR

T1 - Cytotoxic CD8+ T cells in cancer and cancer immunotherapy

AU - Raskov, Hans

AU - Orhan, Adile

AU - Christensen, Jan Pravsgaard

AU - Gögenur, Ismail

PY - 2021

Y1 - 2021

N2 - The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most powerful effectors in the anticancer immune response and form the backbone of current successful cancer immunotherapies. Immune-checkpoint inhibitors are designed to target immune-inhibitory receptors that function to regulate the immune response, whereas adoptive cell-transfer therapies use CD8+ T cells with genetically modified receptors—chimaeric antigen receptors—to specify and enhance CD8+ T-cell functionality. New generations of cytotoxic T cells with genetically modified or synthetic receptors are being developed and evaluated in clinical trials. Furthermore, combinatory regimens might optimise treatment effects and reduce adverse events. This review summarises advances in research on the most prominent immune effectors in cancer and cancer immunotherapy, cytotoxic T cells, and discusses possible implications for future cancer treatment.

AB - The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most powerful effectors in the anticancer immune response and form the backbone of current successful cancer immunotherapies. Immune-checkpoint inhibitors are designed to target immune-inhibitory receptors that function to regulate the immune response, whereas adoptive cell-transfer therapies use CD8+ T cells with genetically modified receptors—chimaeric antigen receptors—to specify and enhance CD8+ T-cell functionality. New generations of cytotoxic T cells with genetically modified or synthetic receptors are being developed and evaluated in clinical trials. Furthermore, combinatory regimens might optimise treatment effects and reduce adverse events. This review summarises advances in research on the most prominent immune effectors in cancer and cancer immunotherapy, cytotoxic T cells, and discusses possible implications for future cancer treatment.

U2 - 10.1038/s41416-020-01048-4

DO - 10.1038/s41416-020-01048-4

M3 - Review

C2 - 32929195

AN - SCOPUS:85090991126

VL - 124

SP - 359

EP - 367

JO - The British journal of cancer. Supplement

JF - The British journal of cancer. Supplement

SN - 0007-0920

ER -

ID: 249022545